Stiff Person Syndrome and Other Anti-GAD–Associated Neurologic Disorders

 

 Buy Article Permissions and Reprints

Abstract

Antibodies directed against glutamic acid decarboxylase (GAD) are present in many patients with stiff person syndrome and increasingly found in patients with other symptoms indicative of central nervous system (CNS) dysfunction, such as ataxia. The classic clinical features of stiff person syndrome include muscular stiffness with superimposed painful muscular spasms. Gait is often impaired. Other CNS disorders associated with GAD antibodies include progressive encephalomyelitis with rigidity and myoclonus (PERM), limbic encephalitis, and even epilepsy. Glutamic acid decarboxylase is the rate-limiting enzyme in the production of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter. Presumably, antibodies directed against GAD impair GABA production, but the precise pathogenic mechanism of GAD-antibody-related neurologic disorders is uncertain. Many patients respond to treatment with immunomodulating therapy. Symptomatic treatment with agents that enhance GABA activity, such as benzodiazepines and baclofen, is also helpful for many patients.

• Reference

• 1 Honnorat J, Saiz A, Giometto B , et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 2001; 58 (2) 225-230
  CrossrefPubMedGoogle Scholar
• 2 Saiz A, Arpa J, Sagasta A , et al. Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity. Neurology 1997; 49 (4) 1026-1030
  CrossrefPubMedGoogle Scholar
• 3 Saiz A, Blanco Y, Sabater L , et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131 (Pt 10) 2553-2563
  CrossrefPubMedGoogle Scholar
• 4 Kono S, Miyajima H, Sugimoto M, Suzuki Y, Takahashi Y, Hishida A. Stiff-person syndrome associated with cerebellar ataxia and high glutamic acid decarboxylase antibody titer. Intern Med 2001; 40 (9) 968-971
  CrossrefPubMedGoogle Scholar
• 5 Hadjivassiliou M, Boscolo S, Tongiorgi E , et al. Cerebellar ataxia as a possible organ-specific autoimmune disease. Mov Disord 2008; 23 (10) 1370-1377
  CrossrefPubMedGoogle Scholar
• 6 Whiteley AM, Swash M, Urich H. Progressive encephalomyelitis with rigidity. Brain 1976; 99 (1) 27-42
  CrossrefPubMedGoogle Scholar
• 7 Pittock SJ, Yoshikawa H, Ahlskog JE , et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 2006; 81 (9) 1207-1214
  CrossrefPubMedGoogle Scholar
• 8 Matà S, Muscas GC, Naldi I , et al. Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J Neuroimmunol 2008; 199 (1-2) 155-159
  CrossrefPubMedGoogle Scholar
• 9 Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010; 67 (4) 470-478
  CrossrefPubMedGoogle Scholar
• 10 Graus F, Saiz A, Lai M , et al. Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology 2008; 71 (12) 930-936
  CrossrefPubMedGoogle Scholar
• 11 McKeon A, Robinson MT, McEvoy KM , et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol 2012; 69 (2) 230-238
  CrossrefPubMedGoogle Scholar
• 12 Liimatainen S, Peltola M, Sabater L , et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia 2010; 51 (5) 760-767
  CrossrefPubMedGoogle Scholar
• 13 Yoshimoto T, Doi M, Fukai N , et al. Type 1 diabetes mellitus and drug-resistant epilepsy: presence of high titer of anti-glutamic acid decarboxylase autoantibodies in serum and cerebrospinal fluid. Intern Med 2005; 44 (11) 1174-1177
  CrossrefPubMedGoogle Scholar
• 14 Peltola J, Kulmala P, Isojärvi J , et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 2000; 55 (1) 46-50
  CrossrefPubMedGoogle Scholar
• 15 Verrotti A, Greco R, Altobelli E, Latini G, Morgese G, Chiarelli F. Anticardiolipin, glutamic acid decarboxylase, and antinuclear antibodies in epileptic patients. Clin Exp Med 2003; 3 (1) 32-36
  CrossrefPubMedGoogle Scholar
• 16 Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342 (5) 314-319
  CrossrefPubMedGoogle Scholar
• 17 Errichiello L, Perruolo G, Pascarella A , et al. Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: a study on 233 patients. J Neuroimmunol 2009; 211 (1-2) 120-123
  CrossrefPubMedGoogle Scholar
• 18 Zivotofsky AZ, Siman-Tov T, Gadoth N, Gordon CR. A rare saccade velocity profile in stiff-person syndrome with cerebellar degeneration. Brain Res 2006; 1093 (1) 135-140
  CrossrefPubMedGoogle Scholar
• 19 Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322 (22) 1555-1560
  CrossrefPubMedGoogle Scholar
• 20 Butler MH, Solimena M, Dirkx Jr R, Hayday A, De Camilli P. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. J Exp Med 1993; 178 (6) 2097-2106
  CrossrefPubMedGoogle Scholar
• 21 Ali F, Rowley M, Jayakrishnan B, Teuber S, Gershwin ME, Mackay IR. Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies. J Autoimmun 2011; 37 (2) 79-87
  CrossrefPubMedGoogle Scholar
• 22 Walikonis JE, Lennon VA. Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. Mayo Clin Proc 1998; 73 (12) 1161-1166
  CrossrefPubMedGoogle Scholar
• 23 Christgau S, Aanstoot HJ, Schierbeck H , et al. Membrane anchoring of the autoantigen GAD65 to microvesicles in pancreatic beta-cells by palmitoylation in the NH2-terminal domain. J Cell Biol 1992; 118 (2) 309-320
  CrossrefPubMedGoogle Scholar
• 24 Reetz A, Solimena M, Matteoli M, Folli F, Takei K, De Camilli P. GABA and pancreatic beta-cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggests their role in GABA storage and secretion. EMBO J 1991; 10 (5) 1275-1284
  PubMedGoogle Scholar
• 25 Hutchinson M, Waters P, McHugh J , et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008; 71 (16) 1291-1292
  CrossrefPubMedGoogle Scholar
• 26 Mas N, Saiz A, Leite MI , et al. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 2011; 82 (12) 1399-1401
  CrossrefPubMedGoogle Scholar
• 27 Raju R, Rakocevic G, Chen Z , et al. Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain 2006; 129 (Pt 12) 3270-3276
  CrossrefPubMedGoogle Scholar
• 28 Ishida K, Mitoma H, Song SY , et al. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol 1999; 46 (2) 263-267
  CrossrefPubMedGoogle Scholar
• 29 Mitoma H, Song SY, Ishida K, Yamakuni T, Kobayashi T, Mizusawa H. Presynaptic impairment of cerebellar inhibitory synapses by an autoantibody to glutamate decarboxylase. J Neurol Sci 2000; 175 (1) 40-44
  CrossrefPubMedGoogle Scholar
• 30 Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 2007; 61 (6) 544-551
  CrossrefPubMedGoogle Scholar
• 31 Rakocevic G, Raju R, Semino-Mora C, Dalakas MC. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology 2006; 67 (6) 1068-1070
  CrossrefPubMedGoogle Scholar
• 32 Dalakas MC. Advances in the pathogenesis and treatment of patients with stiff person syndrome. Curr Neurol Neurosci Rep 2008; 8 (1) 48-55
  CrossrefPubMedGoogle Scholar
• 33 Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology 2008; 71 (24) 1955-1958
  CrossrefPubMedGoogle Scholar
• 34 Holmøy T, Skorstad G, Røste LS, Scheie D, Alvik K. Stiff person syndrome associated with lower motor neuron disease and infiltration of cytotoxic T cells in the spinal cord. Clin Neurol Neurosurg 2009; 111 (8) 708-712
  CrossrefPubMedGoogle Scholar
• 35 Witherick J, Highley JR, Hadjivassiliou M. Pathological findings in a case of stiff person syndrome with anti-GAD antibodies. Mov Disord 2011; 26 (11) 2138-2139
  CrossrefPubMedGoogle Scholar
• 36 Ishida K, Mitoma H, Wada Y , et al. Selective loss of Purkinje cells in a patient with anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia. J Neurol Neurosurg Psychiatry 2007; 78 (2) 190-192
  CrossrefPubMedGoogle Scholar
• 37 Dalakas MC. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol 2005; 252 (Suppl. 01) I19-I25
  CrossrefPubMedGoogle Scholar
• 38 Bonnan M, Cabre P, Olindo S, Signate A, Saint-Vil M, Smadja D. Steroid treatment in four cases of anti-GAD cerebellar ataxia [in French]. Rev Neurol (Paris) 2008; 164 (5) 427-433
  CrossrefPubMedGoogle Scholar
• 39 Lauria G, Pareyson D, Pitzolu MG, Bazzigaluppi E. Excellent response to steroid treatment in anti-GAD cerebellar ataxia. Lancet Neurol 2003; 2 (10) 634-635
  CrossrefPubMedGoogle Scholar
• 40 Nanri K, Okita M, Takeguchi M , et al. Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia. Intern Med 2009; 48 (10) 783-790
  CrossrefPubMedGoogle Scholar
• 41 Vulliemoz S, Vanini G, Truffert A, Chizzolini C, Seeck M. Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. J Neurol Neurosurg Psychiatry 2007; 78 (2) 187-189
  CrossrefPubMedGoogle Scholar